Stalevo® is a combination of levodopa, carbidopa and entacapone. It was initially approved based on pharmacokinetic studies demonstrating bioequivalence with Sinemet® immediate release (IR ...

While patients with Parkinson’s initially start taking oral drugs like levodopa and carbidopa to manage symptoms, these often fail to control symptoms throughout a 24-hour period and tend to ...

[63] A second trial, called Stalevo Reduction in Dyskinesia Evaluation (STRIDE-PD), was designed to evaluate whether Stalevo would delay the onset of dyskinesia compared with levodopa/carbidopa.